Mepicain (Mepivacaine Hydrochloride)

Mepicain is used as a local anesthetic for procedures that require temporary nerve blockade.

• Dental procedures: provides rapid onset anesthesia for tooth extractions and restorative work.
• Regional nerve block: enables targeted anesthesia for limb or facial nerve blocks during surgery.
• Minor surgical procedures: facilitates pain‑free incision and suturing in outpatient settings.

• Mepivacaine hydrochloride exerts its effect by reversibly binding to voltage‑gated sodium channels on neuronal membranes. This blockade prevents the influx of sodium ions during depolarization, thereby inhibiting the generation and propagation of nerve impulses. The result is a temporary loss of sensation in the area supplied by the blocked nerves, with onset typically within minutes and duration of action lasting up to two hours, depending on dose and site.

Mepicain may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tingling or numbness at the injection site.
• Mild dizziness or light‑headedness.
• Transient facial or oral numbness.
• Temporary increase in heart rate.
• Mild nausea or vomiting.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis) with rash, swelling, or airway compromise.
• Cardiovascular collapse or profound hypotension.
• Persistent nerve damage leading to prolonged numbness.
• Seizures or convulsions.
• Cardiac arrhythmias such as ventricular tachycardia.

When using Mepicain, clinicians should observe specific precautions to minimize risk and ensure safe administration.

• Patient assessment: evaluate medical history for cardiac disease, epilepsy, or hypersensitivity to amide anesthetics.
• Dose limitation: avoid exceeding recommended maximum dose for the specific procedure.
• Monitoring: observe vital signs and level of consciousness during and after injection.
• Drug interactions: review concomitant medications that may affect cardiac conduction or CNS excitability.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Store below 25°C: keep in original container, protect from light and moisture.

Mepicain can interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): may potentiate cardiotoxic effects.
• Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis when combined with vasoconstrictors.
• Beta‑blockers: can exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

• Central nervous system depressants (e.g., benzodiazepines, opioids): may enhance sedation.
• Diuretics: may affect plasma electrolyte balance, influencing anesthetic action.
• Calcium channel blockers: possible additive effects on cardiac conduction.